Bayer-sponsored seminar at ISOBM 2003 in Edinburgh will focus on improving the clinical efficacy and cost effectiveness of prostate cancer testing
As a Bronze sponsor of the forthcoming International Society for Oncodevelopmental Biology and Medicine (ISOBM) meeting to be held in Edinburgh from 30 August to 4 September 2003, Bayer Diagnostics is staging a lunchtime seminar for delegates on the subject of prostate cancer risk management.
Chaired by Rainer Neumann of Bayer's European scientific affairs department, the main focus of the seminar will be a presentation by Bernard Croal, consultant in the Department of Clinical Biochemistry at Grampian University Hospitals Trust.
Dr Croal will share his views on improving the clinical and cost effectiveness of prostate cancer testing with an invited audience, focusing particularly on the usefulness of the complexed prostate specific antigen (cPSA) assay which is available for use on Bayer's automated immunoassay analysers.
The ISOBM has an international membership representing 26 countries and provides a forum in which clinical oncologists and scientists in academia and industry can share research findings and review clinical practice in oncology.
Devoted to bridging the gap between basic science and clinical application, the society aims to support discussion and development of novel approaches to clinical problems in cancer.
This will be the 31st annual meeting of the Society, focusing on a broad spectrum of topics ranging from basic biology and translational research to clinical application.
